ESPS is the little white pill for companies showing symptoms of time-consuming regulatory filings. ESPS's (Electronic Submission Publishing Systems)foundation software, CoreDossier, helps phamaceutical, biotechnology, and other companies electronically generate the large documents (up to 500,000 pages) required by regulatory agencies. Users pull data from other databases and compile it into reports that can be edited, published, distributed, and archived. Glaxo Wellcome, Hoechst, and Rhone-Poulenc account for about half of ESPS's sales.ESPS offers related compliance services and continues to expand into utilities, chemicals, and other document-intensive markets. Software firm Adobe Systems owns 49% of ESPS.
1998 over 1997 Sales = $8.6mm: $1.1mm
1998 Net income= $2.9mm
Hey, it's not an inet, but it may be a popper. Available through Schwab. |
